<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02748200</url>
  </required_header>
  <id_info>
    <org_study_id>2015/0169</org_study_id>
    <nct_id>NCT02748200</nct_id>
  </id_info>
  <brief_title>External Beam Radiotherapy for Muscle Invasive Bladder Cancer</brief_title>
  <official_title>Muscle Invasive Bladder Cancer: External Beam Radiotherapy as an Alternative for Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase 1 trial, the investigators will prospectively evaluate 3 different external
      beam radiotherapy (EBRT) schedules. In every schedule, the whole bladder will be treated to
      40 Gray (Gy) in 20 fractions, 5 fractions/week, 4 weeks in total. Based on the summation of
      abnormalities seen on pre- (initial tumor region) and post transurethral resection zone of
      fibrosis Diffusion weighted-magnetic resonance imaging (MRI) images the tumor region is
      delineated and defined as a gross tumor volume (GTV). The GTV will be treated using a
      simultaneous integrated boost (SIB): without extending the 4-weeks treatment period, 3
      different dose levels will be implemented in order to increase the biological equivalent dose
      (BED), as muscle invasive bladder cancer has been shown to be dose-sensitive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3 different dose levels will be implemented in order to increase the biological equivalent
      dose (BED), as muscle invasive bladder cancer has been shown to be dose-sensitive.

        -  Level 1: 57.6 Gray (Gy) (20 x 2.88 Gy, 5 fractions/week, 4 weeks); BED: 61 Gy.

        -  Level 2: 60 Gy (20 x 3.00 Gy, 5 fractions/week, 4 weeks); BED: 64 Gy

        -  Level 3: 62.4 Gy (20 x 3.12Gy, 5 fractions/week, 4 weeks); BED: 67 Gy. Fiducials will be
           implanted at the edges of the postoperative bed during the second transurethral
           resection of the bladder to improve visualization of the gross tumor volume (GTV) during
           external beam radiotherapy (EBRT) and consequently improve treatment delivery accuracy.
           In order to further improve the treatment accuracy, 5 planning Computed Tomographies and
           plans, with different bladder fillings will be made upfront in our study. During
           treatment the plan corresponding best with bladder filling at time of EBRT will be
           selected and delivered.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by Radiation Therapy Oncology Group toxicity scale</measure>
    <time_frame>3 months after radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants free from local relapse assessed on cystoscopy and Magnetic Resonance Imaging</measure>
    <time_frame>12 months after radiotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Toxicity</condition>
  <arm_group>
    <arm_group_label>external beam radiotherapy: Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>57.6 Gray (Gy) (20 x 2.88 Gy, 5 fractions/week, 4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>external beam radiotherapy: dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 Gy (20 x 3.00 Gy, 5 fractions/week, 4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>external beam radiotherapy: dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>62.4 Gy (20 x 3.12Gy, 5 fractions/week, 4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>external beam radiotherapy (EBRT)</intervention_name>
    <description>EBRT: 3 dose escalation levels</description>
    <arm_group_label>external beam radiotherapy: Dose level 1</arm_group_label>
    <arm_group_label>external beam radiotherapy: dose level 2</arm_group_label>
    <arm_group_label>external beam radiotherapy: dose level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological proven diagnosis of muscle invasive bladder cancer

          -  stage &lt;T3b tumours with pathological lymph nodes after extended pelvic lymph node
             dissection

          -  World Health Organisation performance state 0-2

          -  signed informed consent

        Exclusion Criteria:

          -  contra-indication for Diffusion-Weighted-Magnetic resonance imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Fonteyne, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valérie Fonteyne, MD, PhD</last_name>
    <email>valerie.fonteyne@uzgent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Fonteyne, MD PhD</last_name>
      <email>valerie.fonteyne@uzgent.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Ghent</investigator_affiliation>
    <investigator_full_name>Radiotherapie</investigator_full_name>
    <investigator_title>Radiation oncology and experimental cancer research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

